Polyrizon LTD F-1 registration statements

Polyrizon Ltd. filed an amendment to its F-1 registration statement to include a formal auditor consent from Brightman Almagor Zohar & Co.

Polyrizon Ltd. has filed a Form F-1 registration statement for the resale of up to 499,999 ordinary shares by a selling shareholder, primarily issuable upon the exercise of warrants.

Polyrizon Ltd. is registering for resale over 1.5 billion ordinary shares by selling shareholders after a recent private placement.

Polyrizon Ltd. has filed an amendment to its Form F-1 registration statement, detailing the resale of up to 2,419,724 ordinary shares by selling shareholders.

Polyrizon Ltd. is registering for the resale of up to 2,419,724 ordinary shares by selling shareholders, primarily related to warrant exercises, with no proceeds going to the company.

Polyrizon Ltd. files an amendment to its F-1 registration statement, outlining its plans for an initial public offering to further develop its nasal spray medical devices targeting allergies and viral infections.

Polyrizon Ltd. is seeking to go public to fund the development of its nasal spray medical devices designed to block viruses and allergens.

Polyrizon Ltd., a biotech company specializing in nasal spray hydrogels, is planning an initial public offering to fund the development of its medical device product candidates.

Polyrizon Ltd., a biotech firm specializing in nasal spray hydrogels, aims to raise capital through an initial public offering with units priced at $5.20, each including one ordinary share and three warrants.

Polyrizon Ltd. is seeking to go public, offering units consisting of ordinary shares and warrants, as well as pre-funded units for certain investors.

Polyrizon Ltd. files for an initial public offering of units and pre-funded units, along with a resale prospectus for existing shareholders.

Polyrizon Ltd. aims to raise capital through an IPO to further develop its innovative medical device hydrogels delivered as nasal sprays for protection against viruses and allergens.

Polyrizon Ltd. is proceeding with its initial public offering, offering units consisting of ordinary shares and warrants, and pre-funded units, while also registering shares for resale by existing shareholders.